publicações selecionadas
- The impact on clinical outcomes of post-operative radiation therapy delay after neoadjuvant chemotherapy in patients with breast cancer: A multicentric international study
- Her-2 e topoisomerase-II-alpha em tumores de mama e ovário
- Is Independent Clinical Research Possible in Low- and Middle-Income Countries? A Roadmap to Address Persistent and New Barriers and Challenges
- Breast Cancer Treatment Delay in SafetyNet Health Systems, Houston Versus Southeast Brazil
- Takotsubo Syndrome induced by brachytherapy in a patient with endocervical adenocarcinoma.
- Implementando testes de mutação somática em ambiente clínico: recomendações de um painel de especialistas.
- Integrating Adjuvant Radiation with Post-Neoadjuvant Therapies in Early Breast Cancer
- Cost-effectiveness of ribociclib for premenopausal or perimenopausal women with HR+/HER2− advanced breast cancer: A Brazilian public health care system perspective
- Trastuzumab emtansine: a game changer in HER2-positive early breast cancer
- Borderline indications for ovarian suppression: addressing uncertainties with patients
- The Impact of Emotional Intelligence on Enhancing Women?s Leadership Competencies. International Journal of Business and Management
- Pre-treatment MRI tumor features and post-treatment mammographic findings: may they contribute to refining the prediction of pathologic complete response in post-neoadjuvant breast cancer patients with radiologic complete response on MRI?
- Pathologic response at the epicenter of the treatment decision-making process in Human Epidermal Receptor-Type 2 overexpressing (Her2+) Early Breast Cancer (EBC): Challenges and opportunities for financially-constrained healthcare systems
- Telehealth, Social Media, Patient Empowerment, and Physician Burnout: Seeking Middle Ground
- Challenging Outlook of Caring for Adolescents and Young Adults With Cancer in Brazil: Results of a Nationwide Survey
- Subgroup analysis of Brazilian participants of a medical leadership competencies instrument: a cross-sectional survey study of the Latin American Cooperative Oncology Group (LACOG) and the Academy of Leadership Sciences Switzerland (ALSS)
- Patient-accessible test reports in times of instant messaging communication: progress or an additional emotional burden?
- If you can't kill the beast, tame it: Tips for surviving WhatsApp® in medical practice
- Implementing multidisciplinary tumor boards in oncology: a narrative review
- Reply to R. Freitas-Junior et al
- Gene expression signatures in early Breast Cancer: better together with clinicopathological features.
- Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
- Biomarker Data From the Phase III KATHERINE Study of Adjuvant T-DM1 Versus Trastuzumab for Residual Invasive Disease After Neoadjuvant Therapy for HER2-Positive Breast Cancer
- The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115)
- Leadership, Risk-taking, Decision-making: The newest outcomes from the science of leadership
- Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer
- Phase II trial of humanized anti-Lewis Y monoclonal antibody for advanced hormone receptor-positive breast cancer that progressed following endocrine therapy
- Impact of the COVID-19 Pandemic on Cancer Staging: An Analysis of Patients With Breast Cancer From a Community Practice in Brazil
- Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study
- Results of a survey study on health professionals' perceptions of tumor boards in Brazil
- Cross-Cultural Validity Study of a Medical Education Leadership Competencies Instrument in Latin American Physicians: a Multinational Study
- Interfaces between medical practice and trading: lessons from the markets
- More on treatment de-escalation, biomarkers of response in human epidermal growth factor receptor 2 (HER2)-positive breast cancer: long-term outcomes and translational research findings of the PREDIX HER2 trial
- REAL-WORLD TREATMENT OUTCOMES IN HR+ HER2- METASTATIC BREAST CANCER PATIENTS TREATED WITH CDK4/6 INHIBITORS: RESULTS FROM A REFERENCE CENTER IN BRAZIL
- Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE
